Interferon gamma, a naturally occurring protein, could be used in the treatment of osteoporosis, Australian researchers propose. The protein is produced by the body's immune system and stem cells and also used as a treatment for hepatitis C in humans.
A team of scientists of University of Sydney, led by Associate Professor Gustavo Duque, worked with menopausal mice, injecting low doses of interferon gamma in the small mammals. Tests revealed the mice had increased bone mass and decreased bone damage resulting from menopause-associated osteoporosis.
Associate Professor Duque says: "This is a major step in the development of a completely new type of medication for osteoporosis, which stimulates bone formation instead of stopping bone destruction.
Osteoporosis affects an estimated 300 million people worldwide. One in three women over the aged of 50 will experience osteoporotic fractures, as will one in five men of a similar age.
Experts predict, despite the current treatments available, by 2050, the worldwide incidence of hip fracture in men is likely to increase by 310 percent and 240 percent in women.
"This increase is explained by the low rate of diagnosis and treatment for osteoporosis and also to some concerns about the potential side effects of the current treatments and to the similarities between the majority of the osteoporosis medications in terms of their anti-fracture effect and mechanism of action," Associate Professor Duque said.
"The Aging Bone Research Program is dedicated to understand and explaining the process of osteoporosis in older people and to developing comprehensive prevention strategies for falls and fractures in the elderly."
The findings have been published in Journal of Bone and Mineral Research, the official journal of the American Society for Bone and Mineral Research.